FDA to study OTC ozone-depleting asthma inhalers
S
A joint FDA advisory panel this month will discuss essential use determinations for OTC epinephrine metered-dose asthma inhalers that contain ozone-depleting substances (ODSs). According to the agency's notice of the Jan. 24 meeting of the joint Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees, there are some marketed drug products containing epinephrine in a metered-dose inhaler (MDI) form. Under section 610 of the Clean Air Act, MDIs that are not the subject of an essential-use designation cannot be legally distributed. The panelists will discuss the continued need for the essential-use designation for these products. For more information, visit http://www.fda.gov/oc/advisory/accalendar/2006/cder12541d012406.html.
How Mark Cuban Cost Plus Drug Company Is Approaching Drug Pricing Transparency
October 14th 2024Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.
